GlassScriptPhysician profile
Penny S Walker
NPI 1194149070
$4,159.23
in general payments reported to CMS, 2019-2025
29 companies · $577 in 2025
The $577 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,524 · 2022: $857 · 2023: $612 · 2024: $589 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $520.68 | 2021-2024 | |
| Lilly USA, LLC | $458.12 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $413.18 | 2021-2025 | Breztri, Farxiga |
| Abbvie INC. | $408.83 | 2021-2025 | |
| Glaxosmithkline, LLC. | $393.34 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $377.29 | 2021-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $239.83 | 2021-2022 | |
| Exact Sciences Corporation | $176.34 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $160.55 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $156.45 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $151.68 | 2021-2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.92 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $94.80 | 2021-2022 | |
| Almatica Pharma LLC | $87.79 | 2021-2023 | Loreev Xr, Gralise |
| Abbott Laboratories | $67.04 | 2021-2025 | Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $62.26 | 2022-2024 | Repatha, Otezla |
| Mylan Specialty L.P. | $44.57 | 2023-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $40.01 | 2022-2025 | |
| Lundbeck LLC | $24.88 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $24.70 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $23.17 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $22.42 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.20 | 2021 | |
| Grt US Holding, INC. | $17.60 | 2022 | |
| Ibsa Pharma INC. | $17.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.78 | 2023 | Quviviq |
| Amarin Pharma, INC. | $15.07 | 2021 | |
| Dexcom, INC. | $14.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.